Survival outcomes for PFS and OS based on response (≥VGPR vs <VGPR)
| . | Patients, n (%) . | PFS, median . | OS, median . |
|---|---|---|---|
| Entire cohort (N = 840) | |||
| ≥VGPR after 2 cycles | 240 (29) | 28 vs 30, P = .6 | 78 vs 96, P = .1 |
| ≥VGPR after 4 cycles | 350 (42) | 31 vs 29, P = .1 | 89 vs 91, P = .9 |
| ≥VGPR, best response | 552 (66) | 33 vs 22, P < .001 | 102 vs 77, P = .003 |
| Intact monoclonal protein cohort (n = 616) | |||
| ≥VGPR after 2 cycles | 134 (22) | 27 vs 31, P = .3 | 71 vs 97, P = .008 |
| ≥VGPR after 4 cycles | 215 (35) | 32 vs 30, P = .4 | 96 vs 92, P = .6 |
| ≥VGPR, best response | 368 (60) | 34 vs 23, P < .001 | 103 vs 77, P = .03 |
| Light chain evaluable cohort (n = 223) | |||
| ≥VGPR after 2 cycles | 105 (47) | 28 vs 28, P = .5 | 102 vs 77, P = .5 |
| ≥VGPR after 4 cycles | 134 (60) | 30 vs 27, P = .06 | 81 vs 84, P = .5 |
| ≥VGPR, best response | 183 (82) | 30 vs 18, P < .001 | 94 vs 47, P = .008 |
| . | Patients, n (%) . | PFS, median . | OS, median . |
|---|---|---|---|
| Entire cohort (N = 840) | |||
| ≥VGPR after 2 cycles | 240 (29) | 28 vs 30, P = .6 | 78 vs 96, P = .1 |
| ≥VGPR after 4 cycles | 350 (42) | 31 vs 29, P = .1 | 89 vs 91, P = .9 |
| ≥VGPR, best response | 552 (66) | 33 vs 22, P < .001 | 102 vs 77, P = .003 |
| Intact monoclonal protein cohort (n = 616) | |||
| ≥VGPR after 2 cycles | 134 (22) | 27 vs 31, P = .3 | 71 vs 97, P = .008 |
| ≥VGPR after 4 cycles | 215 (35) | 32 vs 30, P = .4 | 96 vs 92, P = .6 |
| ≥VGPR, best response | 368 (60) | 34 vs 23, P < .001 | 103 vs 77, P = .03 |
| Light chain evaluable cohort (n = 223) | |||
| ≥VGPR after 2 cycles | 105 (47) | 28 vs 28, P = .5 | 102 vs 77, P = .5 |
| ≥VGPR after 4 cycles | 134 (60) | 30 vs 27, P = .06 | 81 vs 84, P = .5 |
| ≥VGPR, best response | 183 (82) | 30 vs 18, P < .001 | 94 vs 47, P = .008 |
Data for PFS and OS are in months. Bold type indicates P < .05.